Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Akebia Therapeutics (AKBA) Gains from Investment Securities: 2014-2024

Historic Gains from Investment Securities for Akebia Therapeutics (AKBA) over the last 11 years, with Dec 2024 value amounting to -$622,000.

  • Akebia Therapeutics' Gains from Investment Securities fell 271.03% to -$1.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.4 million, marking a year-over-year increase of 183.52%. This contributed to the annual value of -$622,000 for FY2024, which is 145.70% down from last year.
  • Latest data reveals that Akebia Therapeutics reported Gains from Investment Securities of -$622,000 as of FY2024, which was down 145.70% from $1.4 million recorded in FY2023.
  • Akebia Therapeutics' Gains from Investment Securities' 5-year high stood at $30.2 million during FY2022, with a 5-year trough of -$5.7 million in FY2021.
  • Its 3-year average for Gains from Investment Securities is $10.3 million, with a median of $1.4 million in 2023.
  • As far as peak fluctuations go, Akebia Therapeutics' Gains from Investment Securities plummeted by 304.17% in 2021, and later surged by 632.99% in 2022.
  • Akebia Therapeutics' Gains from Investment Securities (Yearly) stood at $2.8 million in 2020, then plummeted by 304.17% to -$5.7 million in 2021, then spiked by 632.99% to $30.2 million in 2022, then tumbled by 95.50% to $1.4 million in 2023, then plummeted by 145.70% to -$622,000 in 2024.